Drug Profile

Research programme: uveitis therapeutics - EyePoint Pharmaceuticals

Latest Information Update: 28 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator pSivida
Developer EyePoint Pharmaceuticals
Class Eye disorder therapies
Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

28 Mar 2021 No recent reports of development identified for research development in Uveitis in USA (Intravitreous)
28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
07 Feb 2017 Research programme: uveitis therapeutics - pSivida is available for licensing as of 07 Feb 2017. http://www.psivida.com/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com